According to MeiraGTx's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.77103. At the end of 2024 the company had a P/E ratio of -2.78.
Year | P/E ratio | Change |
---|---|---|
2024 | -2.78 | -41.03% |
2023 | -4.71 | 107.39% |
2022 | -2.27 | -82.4% |
2021 | -12.9 | 27.98% |
2020 | -10.1 | -16.39% |
2019 | -12.1 | 448.43% |
2018 | -2.20 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Novocure
NVCR | -7.53 | 99.76% | Jersey |
![]() Novavax NVAX | 2.31 | -161.15% | ๐บ๐ธ USA |
![]() Organovo ONVO | -0.1771 | -95.30% | ๐บ๐ธ USA |
![]() Orchard Therapeutics
ORTX | -2.69 | -28.57% | ๐ฌ๐ง UK |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.